# What happens when you stop a GLP-1? The regain data

October 8, 2026 · Weight Management · 9 min read · https://burnweek.fit/blog/weight-regain-after-stopping-glp1/

> Stopping the injection is not a character test. Regain is common; here is what studies show about its pace and the limited evidence on slowing it.

**Key takeaways**

- A 2026 BMJ meta-analysis of 37 studies (9,341 people) found regain of about 0.4 kg a month after weight-loss drugs stopped, and 0.8 kg a month after semaglutide or tirzepatide.
- Return to starting weight is a projection, not an observation: about 1.7 years across all drugs and 1.5 years for the newer incretin drugs, from trials with at most 12 months of follow-up for those drugs.
- In the STEP 1 extension, people regained 11.6 of the 17.3 percentage points they had lost within a year of stopping semaglutide.
- In SURMOUNT-4, relative to weight at randomization, switching to placebo after 36 weeks of tirzepatide led to a 14.0% gain over 52 weeks; continuing led to a further 5.5% loss.
- In one Copenhagen trial, adding supervised exercise to liraglutide kept more weight off overall, but off-treatment regain did not clearly differ. That is not proof that habits prevent regain.

## After stopping, most of the lost weight returns within about a year and a half — on current projections

If you stop semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), the weight you lost on the drug tends to come back, and in an indirect comparison, faster than it does after a diet program. A 2026 *BMJ* systematic review and meta-analysis of 37 studies with 9,341 participants, found average regain of about **0.4 kg a month** after any weight-management medication stopped. For the newer, more effective incretin drugs (semaglutide and tirzepatide), the rate was **0.8 kg a month**, with a projected return to starting weight about **1.5 years** after the last dose ([West et al., 2026](https://doi.org/10.1136/bmj-2025-085304)).

That projection needs its asterisk up front. The semaglutide-and-tirzepatide subgroup behind it had only eight studies, with at most 12 months of follow-up after stopping. The 1.5-year figure extends an observed trend line forward. Treat it as the best current forecast. It is not a measured endpoint.

If you arrived here from our [guide to calorie deficits](/blog/calorie-deficit-weight-loss), the mechanics are familiar: these drugs make a deficit easier to hold by turning down appetite. When the drug stops, the deficit stops being easy. What follows is what the data says happens next, and what it says about the parts you can influence.

## The meta-analysis in numbers

The *BMJ* review pooled randomized trials, non-randomized trials, and observational studies where people took a weight-loss drug for at least eight weeks and were followed for at least four weeks after stopping. Treatment lasted 39 weeks on average, and follow-up after stopping averaged 32 weeks ([West et al., 2026](https://doi.org/10.1136/bmj-2025-085304)).

| Drug group | Monthly regain after stopping | Estimated regain within one year | Projected return to baseline weight |
|---|---|---|---|
| Any weight-management drug (63 arms) | 0.4 kg (95% CI 0.3–0.5) | 4.8 kg | 1.7 years (1.3–2.1) |
| All incretin drugs (32 arms) | 0.5 kg (0.4–0.7) | 6.0 kg | 1.6 years (1.1–2.1) |
| Semaglutide and tirzepatide (10 arms) | 0.8 kg (0.7–0.9) | 9.9 kg | 1.5 years (1.0–1.9) |
| Behavioral weight programs (earlier review, same team) | slower by ~0.3 kg/month | — | 3.9 years (2.8–4.9) |

Two details in that table are worth reading slowly.

First, the newer drugs regain fastest partly because they took off the most. People on semaglutide or tirzepatide lost 12.3 kg more than controls during treatment, against 5.7 kg for all drugs combined. The drop was bigger, so there was more to come back.

Second, the comparison with diet-and-exercise programs, which is indirect (drawn from different studies and populations), held **independent of how much weight was lost first**. After adjusting for initial loss, regain after drugs was still about 0.3 kg a month faster than after behavioral programs. The authors also projected that cardiometabolic markers such as blood pressure, cholesterol, and HbA1c return to baseline within about 1.4 years of stopping, though they had too little data to run that analysis for the newer drugs specifically.

The review was funded in part by the UK's National Institute for Health and Care Research, not by a drug maker. The trials below were industry-funded.

## Two trials that stopped the drug on purpose

The cleanest evidence comes from trials that took people off the drug and kept measuring.

**STEP 1 extension (semaglutide).** In adults without diabetes, after 68 weeks of weekly semaglutide 2.4 mg plus lifestyle support, treatment was stopped. That included the lifestyle program. The extension followed 327 participants from both arms for another year. In the semaglutide group, average loss on the drug had been 17.3% of body weight. By week 120 they had regained 11.6 percentage points of it, leaving a net loss of 5.6% from where they started. Most cardiometabolic improvements also drifted back toward baseline ([Wilding et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35441470/)). In plain terms: about two-thirds of the loss came back within a year. The trial was funded by the drug's manufacturer, and the extension analyses were exploratory.

**SURMOUNT-4 (tirzepatide).** This was a randomized withdrawal trial in adults without diabetes, alongside diet and activity advice throughout. After 36 weeks of open-label tirzepatide at the maximum tolerated dose (10 or 15 mg), 670 people who had lost an average of 20.9% were randomly assigned either to keep taking it or to switch to placebo for 52 weeks. Measured from their weight at randomization, the placebo group **regained 14.0%** and the group that stayed on the drug **lost a further 5.5%**. (These percentages use a different starting point from the 20.9%, so they can't simply be subtracted.) At the end, 89.5% of those who continued had kept at least 80% of their initial loss, against 16.6% of those switched to placebo ([Aronne et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38078870/)). The trial was also manufacturer-funded.

Note what SURMOUNT-4 does *not* show: that everyone who stops regains everything. Even the placebo group finished the 88 weeks 9.9% below their starting weight. Regain is the average direction, and it is steep, but it varies a lot between people.

> Regain after stopping is not evidence that you did the drug wrong. It is what happens when a treatment that suppresses appetite is removed and the body's own weight defenses are left in charge.

## Why the weight comes back faster than after a diet

The review authors do not claim a single mechanism, and the data cannot isolate one. What is well documented is that weight loss by any route triggers a response that pushes back: hunger rises and energy expenditure falls, a pattern covered in our piece on [set point theory](/blog/set-point-theory-explained). While the drug is active, it counters much of the appetite side of that response. As the medication clears, its appetite-suppressing effect wears off, while the biology that favors regain is still in place.

A behavioral program is different in one practical way: the skills people used to lose the weight are still there after the program ends, even if they fade. A drug's effect fades once it is no longer being taken. That is one plausible reading of why the review found faster regain after drugs even at matched weight loss. It is an interpretation, not a measured cause.

This is also why "regain is physiology" isn't a pep talk. The STEP 1 and SURMOUNT-4 participants were motivated volunteers in closely supervised trials, and they regained anyway. The trials measured a biological response to stopping treatment. They did not measure willpower.

## What might soften the landing — and how strong that evidence is

Here the evidence gets thinner, and it should be read that way. **No trial has shown that any habit reliably prevents regain after stopping a GLP-1 drug.** A few findings point in a useful direction.

**Exercise alongside the drug, in one trial.** In a Copenhagen trial, adults with obesity first lost about 13.1 kg on an eight-week low-calorie diet. They were then randomized to a year of supervised exercise, liraglutide (an older GLP-1 drug), both, or placebo. Measured from randomization to one year after *all* treatment stopped, a period that includes the treatment year, the combination group was 5.1 kg lighter than the liraglutide-alone group. During the off-treatment year alone, regain after the combination differed from liraglutide alone by 2.5 kg, with a confidence interval that included no difference; regain was 6.0 kg larger after liraglutide alone than after exercise alone ([Jensen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38544798/)). So the combination group kept more weight off overall, but whether it regained less after stopping is uncertain. The caveats matter: it used liraglutide rather than semaglutide or tirzepatide, only 109 people came back for the follow-up, and the confidence intervals are wide. Part of the funding came from a foundation linked to the drug's manufacturer.

**Behavioral support during treatment.** In the *BMJ* review, incretin-drug studies that included behavioral support showed 6.7 kg more weight loss during treatment than studies with little or none, a between-study association. After accounting for that larger initial loss, the rate of regain did not differ by support intensity, and the authors found no evidence that support after stopping slowed regain ([West et al., 2026](https://doi.org/10.1136/bmj-2025-085304)). That runs against the intuitive story, and it's why this article won't promise that good habits will hold the line.

**Protein and resistance training.** These matter for what the weight you lose is made of, a question covered in our piece on [protein intake on GLP-1 medications](/blog/protein-intake-on-glp1-medications). They are sensible parts of any maintenance plan. But no withdrawal trial has tested whether they slow regain after the drug stops.

## Planning an exit with your clinician

Whether to stop, taper, or continue is a medical decision, and your prescriber sets the plan. Cost, side effects, supply, pregnancy plans, and other conditions all enter it, and the trial data above is one input among several. SURMOUNT-4's clearest message is that for many people the drug works like other chronic-disease treatments: the effect lasts while the treatment does.

If you and your clinician do plan to stop, some practical steps follow from the data without promising more than it supports:

- **Expect appetite to return, and plan meals for the hungrier version of you.** Portion habits formed while the drug was suppressing appetite may not hold up once it stops.
- **Recalculate your maintenance intake at your new weight.** A smaller body needs fewer calories than your old one did. Our guide to [maintenance calories after dieting](/blog/maintenance-calories-after-dieting) walks through it.
- **Set an early-warning line.** Pick a weight a kilogram or two above your current one, and agree in advance with your clinician what happens if you cross it. The general evidence on [keeping weight off](/blog/how-to-maintain-weight-loss) favors catching regain early, while it is small.
- **Keep the activity you built, or start now.** The only randomized post-stopping evidence in this piece favors exercise, even though it comes from a single trial of an older drug.

None of these steps guarantees you will hold your weight. They are ways to see regain early, while you can still act on it.

## FAQ

### How fast do you regain weight after stopping Ozempic or Wegovy?

In pooled studies, weight came back at about 0.8 kg a month after stopping semaglutide or tirzepatide, roughly 9.9 kg in the first year ([West et al., 2026](https://doi.org/10.1136/bmj-2025-085304)). In the STEP 1 extension, people regained about two-thirds of their semaglutide weight loss within a year of stopping ([Wilding et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35441470/)).

### Will I go all the way back to my starting weight after coming off tirzepatide?

On average, current data projects a return to baseline about 1.5 years after stopping the newer drugs. But that is a projection from studies with at most a year of follow-up, and individuals vary. In SURMOUNT-4, the group switched to placebo was still 9.9% below its starting weight at the end of the trial ([Aronne et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38078870/)).

### Is regain after a GLP-1 faster than after a regular diet?

Yes, in the best comparison available, though it is indirect. The *BMJ* review found regain about 0.3 kg a month faster after drugs than after behavioral weight programs, even after accounting for how much weight had been lost. After behavioral programs, the projected return to baseline was 3.9 years, against 1.7 years for drugs overall.

### Does exercise stop weight regain after stopping a weight-loss drug?

One randomized trial found that people who had supervised exercise alongside liraglutide kept more weight off overall a year after treatment ended, though their regain after stopping did not clearly differ from liraglutide alone ([Jensen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38544798/)). That is encouraging, but it is a single trial of an older drug. It is not proof that exercise prevents regain after semaglutide or tirzepatide.

## Sources

- [West S, Scragg J, Aveyard P, Oke JL, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026. doi:10.1136/bmj-2025-085304](https://doi.org/10.1136/bmj-2025-085304)
- [Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725](https://pubmed.ncbi.nlm.nih.gov/35441470/)
- [Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. doi:10.1001/jama.2023.24945](https://pubmed.ncbi.nlm.nih.gov/38078870/)
- [Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.102475](https://pubmed.ncbi.nlm.nih.gov/38544798/)

Source: BurnWeek — "What happens when you stop a GLP-1? The regain data", https://burnweek.fit/blog/weight-regain-after-stopping-glp1/. Licensed CC BY 4.0: free to quote or reuse with a link to this page.